Compare Shell PLC (SHEL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs GeneDx Holdings Corp — how do they compare? Shell PLC trades at $87.12 (market cap $235.24B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Shell PLC is far larger — about 130.7× GeneDx Holdings Corp's market cap, and Shell PLC pays a 3.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SHEL | WGS | |
|---|---|---|
Market Cap | $235.24B | $1.80B |
Sector | Energy | Technology |
52-Week High | $94.15 | $167.51 |
52-Week Low | $70.31 | $34.51 |
Enterprise Value | $287.77B | $1.80B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $87.20, showing modest daily decline but maintaining strong technical momentum with bullish moving averages. The stock offers attractive valuation with P/E of 13.43 and P/S of 0.94, supported by solid profitability metrics including 7.01% net margin and 10.64% ROE. Recent Q1 2026 earnings beat expectations at $2.44 EPS versus $2.14 forecast, while the company expands LNG operations in the Caribbean and advances Venezuela gas projects.
Shell presents compelling value with 30% upside to consensus price target of $114.13, supported by 69% analyst buy ratings. However, investors face risks from volatile oil prices, Middle East production disruptions, and declining cash flow trends. The current technical overbought condition suggests potential near-term consolidation before further gains.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
